Nintedanib: beneficial agent in post-COVID-19 Pulmonary Fibrosis
Authors
Victoria Țau
Clinical Hospital of Pulmonary Diseases Iași, Iasi, Romania
Andreea Zabară Antal
zabara-antal_andreea@d.umfiasi.ro
Clinical Hospital of Pulmonary Diseases Iași, Iasi, Romania
Doctoral School, Faculty of Medicine, University of Medicine and Pharmacy “Grigore T. Popa”, Iași, Romania
Paula Vasilache Antohi
Clinical Hospital of Pulmonary Diseases Iași, Iasi, Romania
Ioana Adelina Stoian
Clinical Hospital of Pulmonary Diseases Iași, Iasi, Romania
Doctoral School, Faculty of Medicine, University of Medicine and Pharmacy “Grigore T. Popa”, Iași, Romania
Adriana Loredana Pintilie
Clinical Hospital of Pulmonary Diseases Iași, Iasi, Romania
Antigona Carmen Trofor
Clinical Hospital of Pulmonary Diseases Iași, Iasi, Romania
Pulmonary Department, Faculty of General Medicine, University of Medicine and Pharmacy “Grigore T. Popa,”, Iași, Romania
Radu Adrian Crișan-Dabija
Clinical Hospital of Pulmonary Diseases Iași, Iasi, Romania
Pulmonary Department, Faculty of General Medicine, University of Medicine and Pharmacy “Grigore T. Popa,”, Iași, Romania
Language: English
Page range: 90 - 96
Published on: Jun 19, 2024
Published by: Romanian Society of Pneumology
In partnership with: Paradigm Publishing Services
Publication frequency: Volume open
Keywords:
Related subjects:
© 2024 Victoria Țau, Andreea Zabară Antal, Paula Vasilache Antohi, Ioana Adelina Stoian, Adriana Loredana Pintilie, Antigona Carmen Trofor, Radu Adrian Crișan-Dabija, published by Romanian Society of Pneumology
This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 License.